Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as cetuximab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of
colorectal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as
capecitabine, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Giving cetuximab together with capecitabine may kill
more tumor cells.
PURPOSE: This phase II trial is studying how well giving cetuximab together with capecitabine
work in treating patients with metastatic colorectal cancer.